Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,182 across all filing types
Latest filing 2020-12-28 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Lupin launches Meloxicam Capsules.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of Meloxicam Capsules by Lupin Limited, following FDA approval. It is addressed to stock exchanges as a disclosure pursuant to SEBI regulations. The content is a corporate announcement about a product launch and regulatory approval, not a financial report, earnings release, or management discussion. The document length is short (3892 characters) and it is clearly a press release rather than a detailed report or transcript. Therefore, it fits best under Regulatory Filings (RNS), which is the category for general regulatory announcements and disclosures that do not fit other specific categories.
2020-12-28 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing Lupin Limited's receipt of tentative approval from the U.S. FDA for a generic drug product. It is addressed to stock exchanges as a disclosure pursuant to SEBI regulations. The content is a corporate announcement about regulatory approval and product marketing, not a financial report, earnings release, or management discussion. The document length is 4104 characters, which is relatively short and typical for a press release. There is no financial data, no meeting materials, no voting results, no audit information, no legal proceedings, no capital changes, and no executive changes. Therefore, the document fits best into the category of Regulatory Filings (RNS), which is the fallback for general regulatory announcements and disclosures that do not fit other categories.
2020-12-24 English
Lupin Receives Tentative Approval for Efinaconazole Topical Solution.
Regulatory Filings Classification · 95% confidence The document is a press release announcing Lupin Limited's receipt of tentative approval from the U.S. FDA for a generic drug product. It is addressed to stock exchanges as a disclosure pursuant to SEBI regulations. The content is a corporate announcement about regulatory approval and product marketing, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial data. The document length is 4096 characters, which is relatively short and typical for a press release. Therefore, this fits best under the category of a Regulatory Filing (RNS), which covers general regulatory announcements and disclosures that do not fit other specific categories.
2020-12-24 English
Disclosure in respect of allotment of 103855 equity shares under ESOP.
Share Issue/Capital Change Classification · 95% confidence The document is a notification about the allotment of shares under the Employee Stock Option Plan (ESOP) pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It details the number of shares allotted and the resulting increase in issued and paid-up capital. The document is an announcement of a capital change due to share allotment under ESOP, not a full financial report or detailed capital structure update. It fits the category of Share Issue/Capital Change (SHA). The document length is short and it is a direct announcement, not a report publication or certification.
2020-12-23 English
ESOP/ESOS/ESPS
Share Issue/Capital Change Classification · 95% confidence The document is a letter addressed to the National Stock Exchange of India, disclosing the allotment of shares under the Employee Stock Option Plan (ESOP) as per Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It reports the allotment of 103,855 fully paid-up equity shares and the resulting increase in the company's issued and paid-up capital. The document is a formal announcement of a capital change due to share allotment under ESOP, not a full financial report or detailed analysis. The document length is short (1756 characters), and it is clearly an announcement of a share capital change rather than a report or detailed filing. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2020-12-23 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the receipt of U.S. FDA approval for a pharmaceutical product (Rufinamide Oral Suspension) by Lupin Limited. It is addressed to stock exchanges as a disclosure pursuant to SEBI regulations. The content focuses on the approval news and company background, without any financial statements, detailed financial analysis, or regulatory filings. The document length is 3743 characters, which is relatively short and typical for a press release. It does not contain financial results, management discussion, or voting results. It is not an announcement of a report publication but a disclosure of a significant corporate event related to product approval. Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and disclosures that do not fit other specific categories.
2020-12-21 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.